- Conditions
- Migraine
- Interventions
- Elismetrep, Placebo
- Drug
- Lead sponsor
- TriGemX Bio, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 113
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 93 more
Location Directory
Clinical trials in Houston, Texas
This page shows live ClinicalTrials.gov search results for Houston, Texas, with direct links to official study records plus on-page filtering and sorting for broad location searches.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
22488
Shown on this page
12
Current sort
Recently updated
Location scope
Houston, TX
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 181–192 of 22,488 matching trials in Houston, TX.
Live ClinicalTrials.gov results.
Institutions in Houston
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder, Depression Disorders, Depression Disorder, Depression
- Interventions
- CYB003, Psychological Support
- Drug · Behavioral
- Lead sponsor
- Cybin IRL Limited
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Little Rock, Arkansas + 36 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Eteplirsen, Golodirsen, Casimersen
- Drug
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Industry
- Eligibility
- Male only
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2033
- U.S. locations
- 23
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Orange, California + 20 more
- Conditions
- Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7
- Interventions
- Atezolizumab, Biopsy Procedure, Biospecimen Collection, Cetuximab, Cisplatin, Computed Tomography, Docetaxel, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Survey Administration
- Drug · Procedure · Biological + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 613 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 338
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 266 more
- Conditions
- Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
- Interventions
- REGN5678, Cemiplimab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 345 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 24
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 17 more
- Conditions
- Rett Syndrome
- Interventions
- fenfluramine hydrochloride, Placebo
- Drug · Other
- Lead sponsor
- UCB BIOSCIENCES, Inc.
- Industry
- Eligibility
- 5 Years to 35 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 8
- States / cities
- Little Rock, Arkansas • Miami, Florida • Orlando, Florida + 5 more
- Conditions
- Hemophagocytic Lymphohistiocytosis (HLH), Macrophage Activation Syndrome (MAS), Still Disease
- Interventions
- Local laboratory testing, Local Lab Tests
- Other
- Lead sponsor
- Swedish Orphan Biovitrum
- Industry
- Eligibility
- Up to 80 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Los Angeles, California • Miami, Florida + 14 more
- Conditions
- Acral Lentiginous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Mucosal Melanoma
- Interventions
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Therapeutic Conventional Surgery
- Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 815
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 511 more
- Conditions
- Amblyopia
- Interventions
- Luminopia, Eye Patch
- Device · Other
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 4 Years to 7 Years
- Enrollment
- 238 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Scottsdale, Arizona + 58 more
- Conditions
- Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma, Refractory Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8
- Interventions
- Biospecimen Collection, Bone Scan, Computed Tomography, Docetaxel, Eribulin Mesylate, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Paclitaxel, Sacituzumab Govitecan
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 448
- States / cities
- Kingman, Arizona • Phoenix, Arizona • Fort Smith, Arkansas + 306 more
- Conditions
- Lung Cancer, Lung Metastases
- Interventions
- Abenacianine, Near Infrared (NIR) Imaging
- Drug · Other
- Lead sponsor
- Vergent Bioscience, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 8
- States / cities
- Duarte, California • Newport Beach, California • Aurora, Colorado + 5 more
- Conditions
- NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer), ES-SCLC, Small Cell Lung Cancer Extensive Stage, B7H3, Prostate Cancer, HNSCC, mCRPC (Metastatic Castration-resistant Prostate Cancer), Head Neck Cancer Squamous Cell Metastatic, ESCC or Esophageal Adenosquamous Carcinoma, CRC, CRC (Colorectal Cancer)
- Interventions
- [225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging)
- Drug
- Lead sponsor
- Aktis Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 2
- States / cities
- Miami, Florida • Houston, Texas